| Patient | Jackie Robinson |
|---|---|
| Date of birth | 1919-01-31 |
| Identifiers | MRN HR-ML037-SYN-TD; SSN (made up) 000-37-2286 |
| Document date | 1971-07-29 |
| Author | Marcus Delacroix-Hale, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review after the retina consultation and first eye injections: retinal diagnosis, glucose, blood pressure and kidney medicines. [S]
Mr. Robinson returns two days after his first visit, from the retina clinic this morning. Dr. Ostrowski-Lane examined both eyes with dilating drops, used ultrasound to confirm that the right retina is attached behind the blood, and measured the swelling at the center of each retina by OCT. She found proliferative diabetic retinopathy in both eyes with swelling of the macula in both, and bleeding into the gel of the right eye, and gave the first aflibercept injections in both eyes. His eyes are a little sore, as expected. He had no flashes or curtain over his vision. He asked how quickly his sugar should come down, because he wants it fixed at once, and what the injections will do. Chest tightness on stairs is unchanged; the stress test is booked. [S]
| Element | Detail |
|---|---|
| Retina clinic | Proliferative retinopathy with macular edema in both eyes, right vitreous hemorrhage, retina attached; first injections given |
| Symptoms | Mild eye soreness; no flashes or curtain |
| Chest | Tightness on stairs unchanged; stress test booked |
| System | Result | Finding |
|---|---|---|
| Eyes | Positive | Blurred vision; mild soreness after the injections; no flashes |
| Cardiovascular | Positive | Chest tightness on stairs, easing with rest; calf pain after a block |
| Endocrine | Negative | No low blood sugar |
| Psychiatric | Positive | Grieving; sleeps poorly |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1,000 mg oral tablet, one tablet twice daily with meals | One tablet twice daily with meals | Oral route | 1970-03-03 | active | S |
| Insulin glargine 100 units/mL pen, 30 units at bedtime, adjusted by the written plan: 2 units each week while fasting glucose is above 160 mg/dL, and 4 units less for any reading below 70 | At bedtime, by the gradual titration plan | Subcutaneous route | 1970-03-03 | active | S |
| Lisinopril 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1970-03-03 to 1971-07-29 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet daily (increased from 40 mg at intake) | One tablet daily | Oral route | 1971-07-27 | active | S |
| Aspirin 81 mg delayed-release oral tablet, one tablet daily | One tablet daily | Oral route | 1970-03-03 | active | S |
| Glucagon 3 mg nasal powder, one spray into the nose for severe low blood sugar; may repeat once after 15 minutes | As needed for severe low blood sugar | Nasal route | 1971-07-27 | active | S |
| Lisinopril 40 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating | One tablet daily, with sick-day rules | Oral route | 1971-07-29 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgery or a colonoscopy preparation | One tablet daily, with sick-day rules | Oral route | 1971-07-29 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1971-07-29 | Body height | 180 | cm | S |
| 1971-07-29 | Body weight | 103.8 | kg | S |
| 1971-07-29 | Body mass index (BMI) [Ratio] | 32 | kg/m2 | S |
| 1971-07-29 | Systolic blood pressure | 148 | mm[Hg] | S |
| 1971-07-29 | Diastolic blood pressure | 90 | mm[Hg] | S |
| 1971-07-29 | Heart rate | 82 | /min | S |
| 1971-07-29 | Respiratory rate | 16 | /min | S |
| 1971-07-29 | Body temperature | 36.6 | Cel | S |
| 1971-07-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1971-07-29 | Visual acuity best corrected Right eye by ETDRS eye chart | 35 | {letters} | 85 letters is about 20/20; 35 letters is about 20/200 | Low | S |
| 1971-07-29 | Visual acuity best corrected Left eye by ETDRS eye chart | 56 | {letters} | 85 letters is about 20/20; 55 letters is about 20/80 | Low | S |
| 1971-07-29 | Macular grid.center subfield thickness by OCT | 412 | um | 200-300 um | High | S |
| 1971-07-29 | Macular grid.center subfield thickness by OCT | 468 | um | 200-300 um | High | S |
Vital signs recorded on 1971-07-29; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 148/90, pulse 82; weight 103.8 kg |
| Eyes | Mild redness at the injection sites; pupils dilated from the retina examination |
| Cardiovascular | Regular rhythm; no ankle swelling |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Blurred vision in both eyes, worse over two months, with new floaters in the right eye for four days; acuity by Snellen chart 20/200 right and 20/80 left; undilated view poor on the right; urgent retina examination arranged | resolved | confirmed | H53.8 | S — Synthetic presenting finding, superseded by the retinal diagnosis two days later. |
| Tightness in the chest on climbing stairs for two months, easing with rest; ECG without acute change; cardiology evaluation with a stress test arranged | active | confirmed | R07.89 | S — Synthetic presenting finding, superseded by the coronary diagnosis after the stress test. |
| Type 2 diabetes for about fifteen years, on metformin and basal insulin, with hyperglycemia (A1c 10.4%) | active | confirmed | E11.65 | S — Synthetic modern episode linked to his documented diabetes. |
| Proliferative diabetic retinopathy in both eyes with center-involving diabetic macular edema (central subfield 412 microns right, 468 left); best-corrected acuity 35 letters right and 56 letters left | active | confirmed | E11.3513 | S — Synthetic retinal findings anchored to his documented loss of vision. |
| Vitreous hemorrhage in the right eye from proliferative retinopathy; retina attached on ultrasound | active | confirmed | H43.11 | S — Synthetic finding. |
| Hypertension with chronic kidney disease, above goal on lisinopril 20 mg (152/92 mmHg) | active | confirmed | I12.9 | S — Synthetic modern episode linked to his documented high blood pressure. |
| Diabetic kidney disease with albuminuria (urine albumin-to-creatinine ratio 86 mg/g, also raised last year) and eGFR 79 | active | confirmed | E11.22 | S — Synthetic kidney findings. |
| Chronic kidney disease G2 A2 | active | confirmed | N18.2 | S — Synthetic kidney finding. |
| Peripheral artery disease of both legs with calf pain after about one block of walking; faint foot pulses | active | confirmed | E11.51 | S — Synthetic modern episode linked to the documented artery damage in his legs. |
| Diabetic peripheral neuropathy: loss of protective sensation in both feet on monofilament testing | active | confirmed | E11.42 | S — Synthetic modern episode linked to the documented nerve damage in his legs. |
| History of two mild strokes a year ago, without lasting weakness | active | confirmed | Z86.73 | S — Synthetic modern coding of the documented strokes. |
| Hyperlipidemia: LDL 142 mg/dL on atorvastatin 40 mg, far above the goal below 55 mg/dL | active | confirmed | E78.5 | S — Synthetic laboratory finding. |
| Bereavement: his eldest son died in a car crash six weeks ago | active | confirmed | Z63.4 | S — Synthetic modern coding of a documented loss; grief is treated as grief, not as a disorder. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (seated, two readings, large cuff) | Every visit | Completed today | 148/90 |
| Examination | Weight and BMI | Every visit | Completed today | 103.8 kg, BMI 32.0 |
| Imaging | Retina care: acuity, OCT, injections and laser | Monthly at the retina clinic while treating | Completed today | Retina clinic today: acuity 35 letters right and 56 left; central subfield 412 and 468 microns; first injections both eyes |
| Laboratory | Hemoglobin A1c | Every 3 months while not at goal or after a change | Up to date | 10.4% two days ago; next at three months |
| Self-management | Glucose log and low blood sugar review (talking meter) | Every visit | Completed today | Readings 170 to 260 mg/dL; no lows; talking meter ordered |
| Laboratory | Potassium, creatinine and eGFR | Two to four weeks after starting or increasing an ACE inhibitor or SGLT2 inhibitor; then every 6 to 12 months | Ordered | Lisinopril increased and empagliflozin started today; check in four weeks |
| Laboratory | Urine albumin-to-creatinine ratio | Three to six months after a treatment change; then 1 to 4 times a year by risk | Up to date | 86 mg/g two days ago, raised also last year; next at three months |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing a statin; then yearly | Due | Atorvastatin increased to 80 mg two days ago; due in 4 to 12 weeks |
| Medication safety | Medicine safety: low blood sugar, sick-day rules, genital infection, dizziness, cost | Every visit | Completed today | Sick-day rules for empagliflozin and lisinopril written in large print; genital hygiene advice; glucagon shown |
| Referral | Retina consultation | Within 48 hours for new floaters and vision loss with diabetes | Completed today | Seen by Dr. Ostrowski-Lane today |
Goal progress:
Guideline basis: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026); 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026); Diabetic Retinopathy Preferred Practice Pattern (2025); Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) (2016); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, ischemic heart disease, chronic kidney disease and depression monographs (2026)
Follow-up: Stress test as booked. Second injections and review in four weeks with potassium and creatinine and the ankle-brachial index. Call for a curtain over the vision, flashes, eye pain with redness, chest pain at rest, dizziness, or vomiting (hold empagliflozin and lisinopril that day). Next scheduled visit 1971-08-26: four weeks after the new medicines: potassium and creatinine, blood pressure, ankle-brachial index, feet, mood, and the second eye injections. [S]